News

Lucy Therapeutics‘ (LucyTx) overall funding haul has grown to $36 million with the addition of $12.5 million more to support the company’s mitochondrial platform to develop new therapies for Parkinson’s disease.  The total funding will also buttress the development of Lucy’s therapeutic pipeline for Alzheimer’s disease and…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson’s disease. RMAT designation is granted to therapies that have shown potential to treat serious or life-threatening…

A first-of-its kind study has identified key genes in the brain that explain why Black Americans have a lower incidence of Parkinson’s disease, but are at heightened risks for other brain disorders, including stroke and Alzheimer’s. “This landmark work enriches our understanding of the role of genetic ancestry in…

Aside from easing motor symptoms of Parkinson’s disease, deep brain stimulation (DBS) may also slow disease progression by keeping misfolded forms of alpha-synuclein from building up in the brain and harming nerve cells, a preclinical study involving rat brain cells suggests. If the findings hold true in humans, they…

Researchers at the Icahn School of Medicine at Mount Sinai have identified LRRK2 gene mutations as a common element in both inflammatory bowel disease (IBD), an umbrella name for disorders marked by prolonged inflammation of the digestive tract, and Parkinson’s disease. The study also identified genes involved in inflammation…

Low to moderate doses of CAP-003, a gene therapy in the pipeline from Capsida Biotherapeutics, increased levels of glucocerebrosidase (GCase), an enzyme that’s missing or faulty in some people with Parkinson’s disease, in the brain of nonhuman primates. Given as a one-time infusion into the vein, or intravenously,…

Support networks are important for people with Parkinson’s disease, and patients in rural areas don’t always have access to information that would help improve their lives, Central Michigan University researchers said. The researchers are wrapping up a year-long project studying whether creating support networks in underserved U.S. rural communities…

NE3107, now known as bezisterim, eased both motor and nonmotor symptoms when used in combination with a standard carbidopa/levodopa regimen in people with Parkinson’s disease, study data showed. Twice-daily dosing with the anti-inflammatory small molecule being developed by BioVie resulted in better motor function upon waking, more restful…

Genetic variations along with exposure to environmental factors, such as pesticides, may increase Parkinson’s disease in a sex-dependent manner, a study of French farmworkers suggests. “Most cases of Parkinson’s disease don’t arise from a single factor, but rather … a combination of a person’s genes, lifestyle, and what they’re…

Dosing has begun in a Phase 1 clinical trial evaluating the safety and efficacy of IRL757, an oral candidate for apathy treatment in people with Parkinson’s disease and other neurological conditions. Irlab Therapeutics, the therapy’s developer, recently announced the trial’s launch following approval by the Swedish Medical…